TransMedics Group Inc. (TMDX)
TransMedics Statistics
Share Statistics
TransMedics has 33.66M shares outstanding. The number of shares has increased by 2.2% in one year.
| Shares Outstanding | 33.66M |
| Shares Change (YoY) | 2.2% |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 32.43M |
| Failed to Deliver (FTD) Shares | 1.01K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 9.48M, so 28.15% of the outstanding shares have been sold short.
| Short Interest | 9.48M |
| Short % of Shares Out | 28.15% |
| Short % of Float | 34.22% |
| Short Ratio (days to cover) | 12.5 |
Valuation Ratios
The PE ratio is 58.42 and the forward PE ratio is 41.04. TransMedics's PEG ratio is -0.24.
| PE Ratio | 58.42 |
| Forward PE | 41.04 |
| PS Ratio | 4.69 |
| Forward PS | 2.8 |
| PB Ratio | 9.06 |
| P/FCF Ratio | 42.45 |
| PEG Ratio | -0.24 |
Enterprise Valuation
TransMedics has an Enterprise Value (EV) of 2.19B.
| EV / Sales | 4.97 |
| EV / EBITDA | 31.37 |
| EV / EBIT | 44.96 |
| EV / FCF | 44.96 |
Financial Position
The company has a current ratio of 8.3, with a Debt / Equity ratio of 2.01.
| Current Ratio | 8.3 |
| Quick Ratio | 7.52 |
| Debt / Equity | 2.01 |
| Debt / EBITDA | 6.56 |
| Debt / FCF | 9.4 |
| Interest Coverage | 2.6 |
Financial Efficiency
Return on Equity is 15.51% and Return on Invested Capital is 4.98%.
| Return on Equity | 15.51% |
| Return on Assets | 4.41% |
| Return on Invested Capital | 4.98% |
| Revenue Per Employee | $606.51K |
| Profits Per Employee | $48.71K |
| Employee Count | 728 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 3.85 |
Taxes
| Income Tax | 316K |
| Effective Tax Rate | 0.88% |
Stock Price Statistics
The stock price has increased by 5.45% in the last 52 weeks. The beta is 2.13, so TransMedics's price volatility has been higher than the market average.
| Beta | 2.13 |
| 52-Week Price Change | 5.45% |
| 50-Day Moving Average | 73.71 |
| 200-Day Moving Average | 102.79 |
| Relative Strength Index (RSI) | 75.14 |
| Average Volume (20 Days) | 1.23M |
Income Statement
In the last 12 months, TransMedics had revenue of 441.54M and earned 35.46M in profits. Earnings per share was 1.07.
| Revenue | 441.54M |
| Gross Profit | 262.08M |
| Operating Income | 37.5M |
| Net Income | 35.46M |
| EBITDA | 69.95M |
| EBIT | 50.19M |
| Earnings Per Share (EPS) | 1.07 |
Balance Sheet
The company has 336.65M in cash and 458.92M in debt, giving a net cash position of -122.27M.
| Cash & Cash Equivalents | 336.65M |
| Total Debt | 458.92M |
| Net Cash | -122.27M |
| Retained Earnings | -468.24M |
| Total Assets | 804.08M |
| Working Capital | 437.3M |
Cash Flow
In the last 12 months, operating cash flow was 48.8M and capital expenditures 0, giving a free cash flow of 48.8M.
| Operating Cash Flow | 48.8M |
| Capital Expenditures | 0 |
| Free Cash Flow | 48.8M |
| FCF Per Share | 1.47 |
Margins
Gross margin is 59.36%, with operating and profit margins of 8.49% and 8.03%.
| Gross Margin | 59.36% |
| Operating Margin | 8.49% |
| Pretax Margin | 8.1% |
| Profit Margin | 8.03% |
| EBITDA Margin | 15.84% |
| EBIT Margin | 8.49% |
| FCF Margin | 11.05% |
Dividends & Yields
TMDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.71% |
| FCF Yield | 2.36% |
Analyst Forecast
The average price target for TMDX is $112, which is 19% higher than the current price. The consensus rating is "Buy".
| Price Target | $112 |
| Price Target Difference | 19% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 4.54 |
| Piotroski F-Score | 7 |